About This Study
Sometimes after a patient with T cell acute lymphoblastic leukemia (T-ALL) has been treated with chemotherapy the leukemia remains at a very low level. This low level of leukemia is called minimal residual disease (MRD). People with MRD have a higher risk for leukemia coming back again. The purpose of this study is to find out if daratumumab and hyaluronidase can get rid of the MRD.
Need volunteers diagnosed with T cell acute lymphoblastic leukemia that has been treated with chemotherapy, but currently the leukemia is being detected at a very low level. Study team will discuss study details with you.
What Activities Are a Part of this Study?
- Informed Consent Review
- Use of Study Treatments or Placebo
- Review of Medical History
- Physical Examinations
- Study Visits and Consultations
- Laboratory and Imaging Tests
- Specimen Sample Collection
Age & Gender
- 18 - 100 years old
- All Genders
Language
- This study enrolls English and Spanish speakers
Additional Study Information
- No compensation provided
- No reimbursement offered
Study Locations
- Greater Winston-Salem, NC